| |
All patients (n = 62)
|
FOLFOX + Cmab (n = 37)
|
XELOX + Cmab (n = 25)
|
P-value
|
|---|
|
No. women
|
28 (45.2 %)
|
18 (48.9 %)
|
10 (40.0 %)
|
0.502
|
|
Median (range) age (years)
|
66 (34–83)
|
67 (45–83)
|
66 (34–83)
|
0.769
|
|
ECOG performance status
| | |
0.885
|
|
0
|
55 (88.7 %)
|
33 (89.2 %)
|
22 (88.0 %)
| |
|
1
|
7 (11.3 %)
|
4 (10.8 %)
|
3 (12.0 %)
| |
|
Primary tumor site
| | | |
0.193
|
|
Colon
|
36 (58.1 %)
|
18 (48.6 %)
|
8 (32.0 %)
| |
|
Rectum
|
26 (41.9 %)
|
19 (51.4 %)
|
17 (68.0 %)
| |
|
Metastatic site
| | | | |
|
Liver
|
47 (75.8 %)
|
29 (78.4 %)
|
18 (72.0 %)
|
0.136
|
|
Lymph node
|
18 (29.0 %)
|
13 (35.1 %)
|
5 (20.0 %)
| |
|
Lung
|
15 (24.2 %)
|
10 (27.0 %)
|
5 (20.0 %)
| |
|
Other
|
8 (12.9 %)
|
2 (5.4 %)
|
6 (24.0 %)
| |
- Unless indicated otherwise, data show the number of patients in each group, with percentage in parentheses
- ECOG Eastern Cooperative Oncology Group
